Инновационные технологии в лабораторной диагностике ревматических заболеваний

1. <div><p>McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med 2006;3:1242 -8.</p><p>Насонов Е.Л. Современные направления иммунологических исследований при хронических воспалительных и аутоиммунных заболеваниях человека. Тер архив 2001;8:43-6.</p><p>Насонов Е.Л., Александрова Е.Н. Современные стандарты лабораторной диагностики ревматических заболеваний: Клинические рекомендации. М.: ЗАО БиоХимМак, 2006;71 с.</p><p>Wiik A.S., Gordon T.P., Kavanaugh A.F. et al. IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthr Rheum 2004;51:291-8.</p><p>Illei G.G., Tackey E., Lapteva L., Lipsky P.E. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthr Rheum 2004;50:1709-20.</p><p>Illei G.G., Tackey E., Lapteva L., Lipsky P.E. Biomarkers in systemic lupus erythematosus. II Markers of disease activity. Arthr Rheum 2004;50:2048-65.</p><p>Dayer E., Dayer J.M., Roux-Lombard P. Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol 2007;3:12-20.</p><p>Александрова Е.Н.. Лабораторная диагностика. В кн.: Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР- Медиа, 2008;35-62.</p><p>Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. American college of rheumatology ad hoc committee on immunologic testing guidelines. Arthr Rheum 2002;7:429-33.</p><p>Shoenfeld Y., Gershwin M.E., Meroni P.L. Autoantibodies. 2nd ed. Oxford: Elsevier B.V., 2007.</p><p>Conrad K., Schrobler W., Hiepe F., Fritzler M.J. Autoantibodies in systemic autoimmune diseases. A diagnostic reference. In: Conrad K., Sack U. Autoantigens, autoantibodies, autoimmunity. Vol. 2. 2nd ed. Lengerich, Berlin, Bremen, Miami, Riga, Viernheim, Wien, Zagreb: Past Science Publishers, 2007.</p><p>Solomon D.H., Kavanaugh A.J., Schur P.H. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthr Rheum 2002;47:434-44.</p><p>Kavanaugh A.F., Solomon D.H. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthr Rheum 2002;47:546-55.</p><p>Reveille J.D., Solomon D.H. American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthr Rheum 2003;49:399-412.</p><p>Nishimura K., Sugiyama D., Kogata Y. et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.</p><p>Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.</p><p>Bartunkova J., Tesar V., Sediva A. Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol 2003;106:73-82.</p><p>Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthr Rheum 2007;56:1736-44.</p><p>Ursum J., Bos W.H., van de Stadt R.J. et al. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems. Arthr Res Ther 2009;11:R7.</p><p>Valesini G., Alessandri C. Anticitrullinate antibodies and rheumatoid factors: two distinct autoantibody systems. Arthr Res Ther 2009;11:125.</p><p>Vossenaar E.R., Despres N., Lapointe E. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthr Res Ther 2004;6:R142-50.</p><p>Meroni P.L., De Angelis V., Tedesco F. Future Trends. In: Shoenfeld Y., Gershwin M.E., Meroni P.L. Autoantibodies. 2nd ed. Oxford: Elsevier B.V., 2007;823-5.</p><p>Costenbader K.H., Chibnik L.B., Schur P.H. Discordance between erythrocyte sedimentation rate and C-reactive protein measurements: clinical significance. Clin Exp Rheum 2007;25:746-9.</p><p>Yildirim K., Karatay S., Melikoglu M.A. et al. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 2004;34:423-6.</p><p>Combe B., Dougados M., Goupille P. et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthr Rheum 2001;44:1736-43.</p><p>Chen Y.S., Yan W., Geczy C.L. et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoanti-body, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthr Res Ther 2009;11:R39.</p><p>Lyssuk E.Y., Torgashina A.V., Soloviev S.K. et al. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007;601:113-9.</p><p>Dörner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol 2006;77:3-11.</p><p>Fritzler M.J. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006;15:422-7.</p><p>Kantor A.B. Biomarker discovery by comprehensive phenotyping for autoimmune diseases. Clin Immunol 2004;111:186-95.</p><p>Tozzoli R., Bizzaro N. Novel diagnostic methods for autoantibody detection. In: Shoenfeld Y., Gershwin M.E., Meroni P.L. Autoantibodies. 2nd ed. Oxford: Elsevier B.V., 2007;77-82.</p><p>Damoiseaux J., Dähnrich C., Rosemann A. et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 2009;68:228-33.</p><p>Binder S.R. Autoantibody detection using multiplex technologies. Lupus 2006;15:412-21.</p><p>Prestigiacomo T., Binder S.R. Detection of autoantibodies using protein arrays. In: Shoenfeld Y., Gershwin M.E., Meroni P.L. Autoantibodies. 2nd ed. Oxford: Elsevier B.V., 2007;799-807.</p><p>Kingsmore S.F. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006;5:310-20.</p><p>Hueber W., Utz P.J., Steinman L., Robinson W.H. Autoantibody profiling for the study and treatment of autoimmune disease. Arthr Res 2002;4:290-5.</p><p>Robinson W.H., DiGennaro C., Hueber W. et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002;8:295-301.</p><p>Sharp V., Utz P. Technology Insight: can autoantibody profiling improve clinical practice? Nat Clin Pract Rheum 2007;3:96-103.</p><p>Freeman R.G., Raju P.A., Norton S.M. et al. Use of nanobarcodes particles in bioassays. Methods Mol Biol 2005;303:73-83.</p><p>Meheus L., van Venrooij W.J., Wiik A. et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol 1999;17:205-14.</p><p>Pottel H., Wiik A., Locht H. et al. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders. Clin Exp Rheumatol 2004;22:579-88.</p><p>Eissfeller P., Sticherling M., Scholz D. et al. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases. Ann NY Acad Sci 2005;1050:327-39.</p><p>Damoiseaux J., Boesten K., Giesen J. et al. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens. Ann NY Acad Sci 2005;1050:340-7.</p><p>Martins T.B., Burlingame R., von Mü hlen C.A. et al. Evaluation of multiplexed fluorescent microsphere immunoas-say for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 2004;11:1054-9.</p><p>Gilburd B., Abu-Shakra M., Shoenfeld Y. et al. Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation a homogeneous, multiplexed sys tem. Clin Dev Immunol 2004;11:53-6.</p><p>Shovman O., Gilburd B., Barzilai O. et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann NY Acad Sci 2005;1050:380-8.</p><p>Zandman-Goddard G., Gilburd B., Shovman O. et al. The homogeneous multiplexed system-a new method for autoantibody profile in systemic lupus erythematosus. Clin Dev Immunol 2005;12:107-11.</p><p>Rouquette A.M., Desgruelles C., Laroche P. Evaluation of the new multiplexed immunoassay, FIDIS, for simultaneous quantitative determination of antinuclear antibodies and comparison with conventional methods. Am J Clin Pathol 2003;120:676-81.</p><p>Buliard A., Fortenfant F., Ghillani-Dalbin P. et al. [Analysis of nine autoantibodies associated with systemic autoimmune diseases using the Luminex technology. Results of a multicenter study]. Ann Biol Clin (Paris) 2005;63:51-8.</p><p>Gonzalez C., Garcia-Berrocal B., Talavan T. et al. Clinical evaluation of a microsphere bead-based flow cytometry assay for the simultaneous determination of anti-thyroid peroxidase and anti-thyroglobulin antibodies. Clin Biochem 2005;38:966-72.</p><p>Shovman O., Gilburd B., Barzilai O. et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann NY Acad Sci 2005;1050:380-8.</p><p>Binder S.R., Genovese M.C., Merrill J.T. et al. Computer-assisted pattern recognition of autoantibody results. Clin Diagn Lab Immunol 2005;12:1353-7.</p><p>Smith J., Onley D., Garey C. et al. Determination of ANA specificity using the UltraPlex platform. Ann NY Acad Sci 2005;1050:286-94.</p><p>Raza K., Falciani F., Curnow S.J. et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthr Res Ther 2005;7:R784-95.</p><p>Hueber W., Tomooka B.H., Zhao X. et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007;66:712-9.</p><p>Syversen S.W., Goll G.L., Haavardsholm E.A. et al. A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients. Arthr Res Ther 2008;10:R28.</p><p>Jager W., Hoppireijs E.P.A.H., Wulffraat N.M. et al. Blood and synovial fluid cytokines signatures in patients with juvenile idiopatic arthritis a cross-sectional study. Ann Rheum Dis 2007;66:589-98.</p><p>Joos T.O., Schrenk M., Hö pfl P. et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis 2000;21:2641-50.</p><p>Hueber W., Kidd B.A., Tomooka B.H. et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthr Rheum 2005;52:2645-55.</p><p>Rioja I., Hughes F.J., Sharp C.H. et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthr Rheum 2008;58:2257-67.</p><p>Auger I., Balandraud N., Rak J. et al. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 2009;68:591-4.</p><p>Gibbons L.J., Hyrich K.L. Biologic therapy for rheumatoid arthritis. Clinical efficacy and predictors of response. Blodrugs 2009;23:111-24.</p><p>Bansard C., Lequerre T., Daveau M. et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford) 2009, doi:10.1093/rheumatology/kep112.</p><p>Atzeni F., Puttini P., Dell'Acqua D. et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthr Res Ther 2006;8:R3.</p><p>Bobbio-Pallavicini F., Alpini C., Caporali R. et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthr Res Ther 2004;6:R264-72.</p><p>Klareskog L., Moreland L.W., Cohen S.B. et al. Safety and efficacy of over 10 years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann Rheum Dis 2008;67(Suppl. II):175.</p><p>Blank N., Max R., Briem S. et al. Combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):188.</p><p>Jones G., Gu J.R., Lowenstein M. et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the ambition study. Ann Rheum Dis 2008;67(Suppl. II):89.</p><p>Levi M., Frey N., Grange S. et al. Reduction in inflammatory biomarkers with increasing exposure to the IL-6 inhibitor, tocilizumab, in patients with rheumatoid arthritis: graphical analysis of pooled data. Ann Rheum Dis 2008;67(Suppl. II):192.</p><p>Beaulieu A., McKay J., Pavelka K. et al. Treatment with the humanized anti-interleukin-6 receptor antibody tocilizumab results in rapid improvements in the signs and symptoms of rheumatoid arthritis: results from a pooled analysis of clinical trial data from option and toward. Ann Rheum Dis 2008;67(Suppl. II):195.</p><p>Wolbink G.L., Voskuyl A.E., Lems W.F. et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.</p><p>Bruns A., Nicaise-Roland P., Hayem G. et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009;76:248-53.</p><p>Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009;8:515-9.</p><p>Bobbio-Pallavicini F., Caporali R., Alpini C. et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-7.</p><p>Cambridge G., Stohl W., Leandro M.J. et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthr Rheum 2006;54:723-32.</p><p>Jonsdottir T., Gunnarsson I., Risselada A. et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4.</p><p>Leandro M.J., Cambridge G., Edwards J.C. et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5.</p><p>Vallerskog T., Gunnarsson I., Widhe M. et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62-74.</p><p>Ng K.P., Cambridge G., Leandro M.J. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62.</p><p>Lindholm C., Bö rjesson-Asp K., Zendjanchi K. et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-33.</p><p>Teng Y.K., Levarht E.W., Hashemi M. et al. Immunohistochemical analysis as a mean to predict responsiveness to rituximab treatement. Arthr Rhem 2007;56:3909-18.</p><p>Dass S., Rawstron A.C., Vital E.M. et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthr Rhem 2008;58:2993-9.</p><p>Anolik J.H., Barnard J., Owen T. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthr Rheum 2007;56:3044-56.</p><p>Sekigawa I., Yanagida M., Iwabuchi K. et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin Exp Rheumatol 2008;26:261-7.</p><p>Dwivedi R.C., Dhindsa N., Krokhin O.V. et al. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthr Res Ther 2009;11:R32.</p><p>Fabre S., Guisset C., Tatem L. et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009;155:395-402.</p><p>Fabre S., Dupuy A.M., Dossat N. et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008;153:188-95.</p><p>Blom M., Wenink M.H., Huijbens R.J.F. et al. Altered ciculating cytokine pattern after administration of rituximab is correlated with response to therapy in rheumatoid arthritis. Abstract Book ACR 2008. Rituximab abstracts, abstr.764: 26.</p><p>Hueber W., Tomooka B.H., Batliwalla F. et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthr Res Ther 2009;11:R76.</p><p>Parker A., Izmailova E.S., Narang J. et al. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol 2007;34:1817-22.</p><p>Lindberg J., af Klint E., Catrina A.I. et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthr Res Ther 2006;8:R179.</p><p>Wijbrandts C.A., Dijkgraaf M.G., Kraan M.C. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumor necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008;8:1139-44.</p><p>Van der Pouw Kraan T.C., Wijbrandts C.A., van Baarsen L.G. et al. Responsiveness to anti-tumor necrosis factor α therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008;67:563-6.</p><p>Gutierrez-Roelens I., Durez P., Toukap A.N. Effects of rituximab on global gene expression profiles in synovial biopsies obtained from rheumatoid arthritis patients. Abstract Book ACR 2008. Rituximab abstracts, abstr. 1191:38.</p><p>Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T. et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.</p><p>Menzies D., Pai M., Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54.</p><p>Kavanaugh A., Firestein G.S., Boyle D. Biomarkers in rheumatology: promise and pitfalls. Future Rheumatol 2008;3:303-5.</p><p>Bossuyt X., Louche C., Wiik A. Standardisation in clinical laboratory medicine: an ethical reflection. Ann Rheum Dis 2008;67:1061-3.</p></div><br />